The addition of a new indication for second-line treatment of large B-cell lymphoma for Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel) is expected to nearly double the number of US LBCL patients eligible for therapy with the chimeric antigen receptor T-cell (CAR-T), according to the Gilead Sciences, Inc. subsidiary.
Yescarta was cleared for the relapsed or refractory LBCL indication on 1 April, making it the first CAR-T agent to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?